Psychiatric manifestations in moyamoya disease: more than a puff of smoke? a systematic review and a case-reports meta-analysis.

Autor:	Saccaro LF; Psychiatry Department, Geneva University Hospital, Geneva, Switzerland.; Psychiatry Department, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Mallet C; Psychiatry Department, Geneva University Hospital, Geneva, Switzerland., Wullschleger A; Psychiatry Department, Geneva University Hospital, Geneva, Switzerland.; Psychiatry Department, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Sabé M; Psychiatry Department, Geneva University Hospital, Geneva, Switzerland.; Psychiatry Department, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2024 Mar 21; Vol. 15, pp. 1371763. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024).
DOI:	10.3389/fpsyt.2024.1371763
Abstrakt:	Introduction: Moyamoya disease (MMD) is a life-threatening condition characterized by stenosis of intracranial arteries. Despite the frequency and the impact of psychiatric symptoms on the long-term prognosis and quality of life of MMD patients, no systematic review on this topic exists. Methods: This systematic review and meta-analysis included 41 studies (29 being case reports), from PubMed, Scopus, Embase until 27/3/2023, on MMD patients exhibiting psychiatric symptoms. Results: Despite a fair average quality of the articles, quantitative synthesis through logistic regression was possible only for case reports, due to heterogeneity between the other studies. Psychosis, the most frequent psychiatric symptom reported in case reports, was more frequent in MMD patients with left hemisphere involvement. Neurological symptoms occurrence increased the odds of MMD diagnosis preceding psychiatric symptoms. Psychiatric symptoms are highly prevalent in MMD patients and are relatively often the only presenting symptoms. Discussion: We discuss the diagnostic, therapeutic, and prognostic implications of recognizing and characterizing specific psychiatric symptoms in MMD, outlining preliminary guidelines for targeted pharmacological and psychotherapeutic interventions. Lastly, we outline future research and clinical perspectives, striving to enhance the oft-overlooked psychiatric care for MMD patients and to ameliorate their long-term outcome. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023406303. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Saccaro, Mallet, Wullschleger and Sabé.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu